Stock Analysis
AstraZeneca PLCAZN
P/E 25.09×· 5Y range 11.80–1,968.80×· 35th percentile of history
Sector: Healthcare · Industry: Drug Manufacturers - General
AnalystsStrong Buy35 analystsP/E 25.1× sits at the 35th percentile of its 5.0978781656399725-year history.
Cash covers 15% of debt · FY 2025.
PMP Verdict
High quality, fairly valued
Strengths
- Growth95
- Quality85
Strong fundamentals at a reasonable valuation.
Bull Case
- ✓ROE 20.3% — efficient capital deployment
- ✓Revenue CAGR 11.9% — durable top-line growth
- ✓Interest coverage 12.7× — debt well covered
What's happening with AZN
Profile
Strong growth and earnings quality.
How is each axis scored?
- Valuation64/100 · Moderate
- P/E vs own history (35th pct)20/25
- FCF yield (4.2%)12/25
- P/S (4.3x)20/25
- EV/EBIT (19.7x)12/25
- Growth95/100 · Strong
- Revenue CAGR (11.9%)20/25
- Net income CAGR (209.1%)25/25
- EPS CAGR 5Y (267.5%)25/25
- Fwd implied growth (64.5%)25/25
- Profitability72/100 · Moderate
- ROIC (14.5%)12/25
- ROE (20.3%)20/25
- Net margin (17.4%)20/25
- Operating margin (24.3%)20/25
- Financial Health61/100 · Moderate
- Altman Z (2.20)18/25
- Current ratio (0.89)6/25
- Interest coverage (12.7x)25/25
- Net cash / debt (D/A 24%)12/25
- Quality85/100 · Strong
- Piotroski F (5/9)15/25
- Beneish M (-2.66)25/25
- FCF conversion (104%)25/25
- Margin stability (σ 6.1%)20/25
- Moat68/100 · Moderate
- ROIC >12% years (2/5 yrs)6/25
- Median gross margin (81.7%)25/25
- FCF-positive years (5/5 yrs)25/25
- Worst-year net margin (worst 0.3%)12/25
About AstraZeneca PLC
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. Show more
The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
Employees: 96,100 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
64BP/E (TTM)24.9xB
Grade B: FairPrice / TTM EPS (own statements) — vs own 5Y history: 11.8x–1968.8x · 35th pct
P/FCF32.6xC
Grade C: ExpensivePrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield4.2%C
Grade C: LowTTM (OCF − CapEx) / Market Cap — vs own 5Y history: 3.7%–11.7% · 17th pct
P/S (TTM)4.34xB
Grade B: FairPrice / TTM Revenue (own statements) — vs own 5Y history: 1.9x–5.9x · 36th pct
EV/EBIT19.7xC
Grade C: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 9.6x–84.7x · 35th pct
EV/Sales4.6xB
Grade B: FairEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E15.1xB
Grade B: FairPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio5.06xC
Grade C: ExpensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio2.36C
Grade C: ExpensiveFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield1.94%A
Grade A: PaysTTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio46.9%A
Grade A: SafeDividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
72B+ROIC14.5%C
Grade C: AverageNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE20.3%A
Grade A: StrongReturn on Equity. Neg. equity = heavy buybacks
ROA9.1%C
Grade C: AverageReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin17.4%A
Grade A: HighNet Income / Revenue
Operating Margin24.3%C
Grade C: AverageTTM EBIT / TTM Revenue
Gross Margin81.7%A
Grade A: PremiumGross Profit / Revenue
FCF Margin18.2%A
Grade A: HighFCF / Revenue
True FCF Margin17.5%A
Grade A: HighTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
95A+Revenue CAGR11.9%C
Grade C: OkCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR209.1%A
Grade A: HighCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)267.5%A
Grade A: HighCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth64.5%A
Grade A: HighAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)—
Share count change over 5Y
SBC / Net Income3.6%A
Grade A: LowStock-based comp/Net income. >30% = dilution risk
SBC / Revenue0.6%A
Grade A: LowTTM stock-based comp / TTM Revenue
Financial Health
61BAltman Z-Score2.20C
Grade C: Gray zoneBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio0.89xD
Grade D: LowCurrent Assets/Liabilities
Quick Ratio0.67xC
Grade C: Ok(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage12.7xA
Grade A: StrongEBIT/Interest. >10 Strong
Debt Repayment2.6yA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBIT1.9xA
Grade A: LowLeverage. <2x Low, >4x High
Debt/Equity0.64xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.15xD
Grade D: ThinCash covers how much of total debt. >1 = could repay all debt from cash
Quality
85APiotroski F-Score5/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-2.66A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion104.3%A
Grade A: StrongFCF / Net Income
Margin Stability6.1%A
Grade A: StableEBIT margin std deviation. Lower = stable
Capex / Revenue5.2%C
Grade C: AverageTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.54xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 7 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Sharma Mani Filed | Sharma Mani | Grant / award | +2 | |
Sharma Mani Filed | Sharma Mani | Grant / award | +1 | |
Sharma Mani Filed | Sharma Mani | BuyOpen market buy | +20 | |
Sharma Mani Filed | Sharma Mani | Grant / award | +2 | |
Sharma Mani Filed | Sharma Mani | Grant / award | +2 |
Show 2 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Sharma Mani Filed | Sharma Mani | Grant / award | +1 | |
Sharma Mani Filed | Sharma Mani | SellOpen market sale | -11893 |
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
68BROIC >12% Years2/5 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)81.7%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years5/5 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor0.3%C
Grade C: ModerateWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$6.59
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$3.20
Cash & short-term investments per share (Finnhub)
Book Value / Share$32.43
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$32.35B
Total debt obligations (short + long term)
Cash & Equiv.$4.97B
Cash and short-term investments
Net Debt$27.38B
Total Debt minus Cash. Negative = Net Cash position
Total Equity$50.37B
Shareholders' equity (book value)
Asset / Liability1.77xC
Grade C: AdequateTotal Assets / Total Liabilities
Market
Market Cap$254.67B
Current Market Capitalization
Beta1.27C
Grade C: VolatilePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Dec 2025 · Ratio snapshot Oct 17, 2026
Key Insights: AstraZeneca PLC (AZN)
AZN is down 0.76% at the last close. Piotroski F-Score of 5/9 indicates mixed fundamentals for AstraZeneca PLC. Altman Z-Score of 2.20 falls in the grey zone (1.81–2.99) — financial distress is unlikely but not ruled out. Beneish M-Score of -2.66 suggests a low likelihood of earnings manipulation.
- AstraZeneca PLC converts about 18% of revenue into free cash flow — strong cash generation.
- Takes ~2.6 years to repay net debt from free cash flow.
- Return on equity of 20.3% is well above the market average.
See how AZN ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all AZN moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 15 | Pre-market | 167.57 | +3.42% | 2.28 |
| Oct 15 | Regular | 167.44 | +3.34% | 2.23 |
| Oct 14 | Regular | 162.04 | +3.99% | 3.20 |
| Oct 14 | After-hours | 161.62 | +3.72% | 3.00 |
| Sep 23 | Regular | 163.63 | -2.82% | -2.11 |
Frequently Asked Questions about AZN
What is the current AstraZeneca PLC (AZN) stock price?
AZN is trading at $165.41 at the last market close, down 0.76% on the session. PreMarketPrice tracks AZN pre-market, intraday and after-hours prices.
Is AZN stock a buy right now?
PreMarketPrice's quantitative model rates AstraZeneca PLC's financial health at 61/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is AZN stock overvalued?
AstraZeneca PLC trades at a trailing P/E of 24.9 and our valuation score rates it 64/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does AstraZeneca PLC report earnings?
No confirmed earnings date is currently scheduled for AZN. The Earnings section lists recent reports and updates as dates are announced.
What sector does AstraZeneca PLC operate in?
AstraZeneca PLC operates in the Healthcare sector, within the Drug Manufacturers - General industry. The Related Stocks section lists sector peers for comparison.
What does AstraZeneca PLC do?
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999.
About AstraZeneca PLC (AZN) Stock
AstraZeneca PLC (AZN) is a US-listed stock operating in the Healthcare sector, specifically the Drug Manufacturers - General industry. As of the latest update, AstraZeneca PLC is trading at $165.41, down 0.76% on the day with a market capitalization of $254.7 billion. The financial health score for AZN is 61/100, which indicates good financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for AZN stock.
AZN Stock Analysis & Key Metrics
On PreMarketPrice, you can track AstraZeneca PLC (AZN) across multiple dimensions:
- Pre-market price & movement: Real-time AZN stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for AZN with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for AstraZeneca PLC across multiple reporting periods.
- Financial health score: A composite score of 61/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for AZN.
- Sector peers: Compare AZN against 6 other healthcare stocks on key financial metrics.
Is AZN a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate AstraZeneca PLC (AZN) as an investment. The financial health score of 61/100 suggests good financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.AstraZeneca PLC (AZN) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.